Risk factors for radiographic progression in psoriatic arthritis: Subanalysis of the randomized controlled trial ADEPT

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Gladman, Dafna D ^a   Mease, Philip J ^b   Choy, Ernest H S ^c   Ritchlin, Christopher T ^d   Perdok, Renee J ^e   Sasso, Eric H ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b SWEDISH MEDICAL CENTER   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ROCHESTER   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; JOINT DEGENERATION; JOINT EROSION; JOINT RADIOGRAPHY; JOINT SPACE NARROWING; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SHARP SCORE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOGRAPHY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 77953244628     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3049     Document Type: Article

References (26)

1. Gladman DD. Psoriatic arthritis clinical features. Psoriatic Arthritis and Reactive Arthritis 2007, 9-18. St Louis, MO: Mosby Elsevier, Ritchlin CT, Fitzgerald O.
2. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med 1987, 62:127-141.
3. Kane D, Stafford L, Bresniham B, Fitzgerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003, 42:1460-1468. 10.1093/rheumatology/keg384, 14523223.
4. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003, 62:68-70. 10.1136/ard.62.1.68, 1754292, 12480674.
5. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003, 42:778-783. 10.1093/rheumatology/keg217, 12730539.
6. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007, 66:370-376. 10.1136/ard.2006.056457, 1856017, 16916855.
7. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000, 9:1511-1522. 10.1517/13543784.9.7.1511, 11060756.
8. Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballino Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991, 30:245-250. 10.1093/rheumatology/30.4.245, 1863819.
9. Ali Y, Tom BDM, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum 2007, 56:2708-2714. 10.1002/art.22800, 17665458.
10. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998, 41:1103-1110. 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N, 9627021.
11. Gladman DD. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 2003, 33:29-37. 10.1053/sarh.2002.50024, 12920694.
12. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005, 64(Suppl 2):ii78-ii82. 10.1136/ard.2004.034157, 1766864, 15708944.
13. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, . Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of the ADEPT trial. Arthritis Rheum 2005, 52:3279-3289. 10.1002/art.21306, 16200601, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
14. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007, 56:476-488. 10.1002/art.22379, 17265483.
15. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272. 10.1002/art.20335, 15248226.
16. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698-2707. 10.1002/art.22805, 17665424.
17. Kavanaugh A, Antoni CE, Gladman DD, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, van der Heijde D. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038-1043. 10.1136/ard.2005.045658, 1798249, 16439444.
18. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, Pepys MB, Limburg PC. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997, 24:20-27.
19. Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M, . Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710. 10.1002/art.21678, 16508926, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
20. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT, . for the PREMIER investigators The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37. 10.1002/art.21519, 16385520, for the PREMIER investigators.
21. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery J. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967. 10.1002/art.23945, 18821687.
22. Mease PJ, Ory P, Sharp J, Ritchlin CT, van den Bosch F, Wellborne F, Birbara C, Thomson G, Perdok R, Medich J, Wong R, Gladman DD. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009, 68:702-709. 10.1136/ard.2008.092767, 2663711, 18684743.
23. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831. 153764, 12639988.
24. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005, 208:228-251. 10.1111/j.0105-2896.2005.00338.x, 16313352.
25. Landewé R, van der Heidje D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006, 54:3119-3125. 10.1002/art.22143, 17009230.
26. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009, 36:1429-1441. 10.3899/jrheum.081018, 19369462.